EGFR-targeted therapies, including mAbs and small-molecule TKIs, have shown promising efficacy in a variety of tumor therapies, including non-small cell lung cancer, HER2-positive breast cancer, and head and neck cancer [28–30]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.